Claims for Patent: 9,549,538

Summary for Patent: 9,549,538

Title:	Transgenic animal for production of antibodies having minimal CDRs
Abstract:	A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
Inventor(s):	Harriman; William Don (Alameda, CA), Etches; Robert (Oakland, CA), Leighton; Philip A. (San Francisco, CA)
Assignee:	CRYSTAL BIOSCIENCE, INC. (Emeryville, CA)
Application Number:	15/188,724
Patent Claims:	1. A method comprising: (A) immunizing a transgenic non-human animal with an antigen, wherein the transgenic non-human animal uses gene conversion for developing its primary antibody repertoire and the transgenic non-human animal comprises a genome comprising a recombinant immunoglobulin light chain (IgL) locus comprising: a) a functional (IgL) gene comprising a nucleic acid encoding a light chain variable region comprising: i) light chain CDR1, CDR2 and CDR3 regions; and ii) a light chain framework; and, b) a plurality of pseudogenes that encode light chain variable regions each comprising: i) light chain CDR1, CDR2 and CDR3 regions; and ii) a light chain framework region that is identical in amino acid sequence to the light chain framework of a) (ii); wherein said recombinant IgL locus comprises: in operable linkage: an intron region, a constant domain region-encoding region and a 3'untraslated region; wherein at least part of said intron region is endogenous to the genome of said transgenic animal; and said nucleic acid of a) and pseudogene of b), are exogenous to the genome of said transgenic animal, wherein each amino acid residue of the CDRs encoded by the pseudogenes of b) and each amino acid residue of the CDRs of the light chain variable region of a) are selected from the same group of 2 to 5 amino acid residues, wherein said plurality of pseudogenes are operably linked to said functional IgL gene and donate nucleotide sequences to the nucleic acid of a) by gene conversion in said transgenic animal; and wherein said transgenic animal expresses a recombinant immunoglobulin comprising a diversified form of said functional IgL variable region; and (B) obtaining from said transgenic animal an antibody that specifically binds to said antigen. 2. The method of claim 1, further comprising: making hybridomas using cells of said transgenic animal; and screening said hybridomas to identify a hybridoma that produces an antibody that specifically binds to said antigen. 3. The method of claim 1, further comprising amplifying the heavy and light chain variable region-encoding nucleic acid from lymphocytes of said transgenic animal, introducing the amplified nucleic acid into a cell and expressing the nucleic acid in said cell, thereby producing a recombinant antibody comprising the heavy and light chain variable region. 4. The method of claim 1, wherein said antibody is humanized. 5. The method of claim 1, wherein the genome of the transgenic animal further comprises a recombinant immunoglobulin heavy (IgH) locus comprising: c) a functional IgH gene comprising a nucleic acid encoding a heavy chain variable region comprising: i) a heavy chain CDR1, CDR2 and CDR3 regions; and ii) a heavy chain framework; and d) a plurality of pseudogenes that encode heavy chain variable regions each comprising: i) a heavy chain CDR1, CDR2 and CDR3 regions; and ii) a heavy chain framework region that is identical in amino acid sequence to the heavy chain framework of a) (ii); wherein each amino acid residue of the CDRs encoded by the pseudogenes of d) and each amino acid residue of the CDRs of the heavy chain variable region of c) are selected from the same group 2 to 5 amino acid residues, wherein said recombinant IgH locus comprises: in operable linkage: an intron region, a constant domain region-encoding region and a 3'untraslated region; wherein said intron region is endogenous to the genome of said transgenic animal; and said nucleic acid of c) and pseudogene of d), are exogenous to the genome of said transgenic animal, wherein said plurality of pseudogenes are operable linked to said functional IgH gene and donate nucleotide sequences to the nucleic acid of c) by gene conversion in said transgenic animal and wherein said transgenic animal expresses a recombinant immunoglobulin comprising a diversified form of said functional IgH variable region. 6. The method of claim 1, wherein: at least one of the 2 to 5 amino acids in said group is a tyrosine or tryptophan residue, and at least one of the 2 to 5 amino acids in said group is an alanine, glycine or serine residue. 7. The method of claim 1, wherein the amino acid sequence of the framework of the antibody is least 95% identical to a human germline framework. 8. The method of claim 1, wherein the framework of the antibody is identical to a human germline framework. 9. The method of claim 1, wherein the framework of the antibody is from the animal. 10. The method of claim 1, wherein the amino acid sequence of the framework of the antibody is a humanized framework. 11. The method of claim 1, wherein the constant region of the antibody is a human constant region. 12. The method of claim 1, wherein said immunoglobulin light chain locus comprises: in operable linkage: an intron region, a constant domain-encoding region and a 3' untranslated region; wherein said intron region, said constant domain-encoding region and said 3' untranslated region are endogenous to the genome of said transgenic animal; and, said nucleic acid of a) and pseudogenes of b), wherein said nucleic acid of a) and pseudogenes of b) are exogenous to the genome of said transgenic animal. 13. The method of claim 1, wherein said immunoglobulin light chain locus comprises at least 10 of said pseudogenes. 14. The method of claim 1, wherein at least one of said plurality of pseudogenes of b) is in reverse orientation relative to the nucleic acid of a). 15. The method of claim 1, wherein the animal is a chicken.

Details for Patent 9,549,538

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2029-08-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2029-08-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2029-08-13